KR20070112546A - Food composition comprising extracts from lycium chinenses mill - Google Patents

Abstract

A food composition containing Lycium chinense extract is provided to be used as food for improving disorders associated with hyperlipidemia or hypercholesterolemia in climacteric women without side effects. A food composition improving hyperlipidemia or hypercholesterolemia contains an extract of Lycium chinense. The Lycium chinense extract is prepared by adding 200 to 250g leaf of Lycium chinense to 3L distilled water, heating at 100deg.C for 2.5hr, concentrating under reduced pressure, filtering and freeze-drying. An effective amount of the food composition is 0.1 to 40mg/kg/day per an adult.

Description

Food composition comprising extract from Lycium chinenses Mill.

1 is a graph showing weight changes in rats.

2 is a graph showing the effect of LCF and LCL on uterine body weight in ovarian isolated mice.

3 is a cross-sectional picture of the uterus of the test model.

4 shows the effect of LCF and LCL on serum osteocalcin in uterine isolated mice.

5 is a graph showing the effect of LCF and LCL on alkaline phosphatase activity in uterine isolated mice.

6 is a scanning electron micrograph of each test model.

7 is a photograph showing the histological changes of each test model.

The present invention relates to a composition comprising a wolfberry extract, and more particularly to the use of a composition comprising a wolfberry extract. Goji berry extract of the present invention is derived from a natural product has no side effects and significantly improves hyperlipidemia, hypercholesterolemia can be used as a food ingredient for the treatment of related diseases.

Goji is a fruit of the Goji berry family belonging to the branch family, has a unique sense of taste and has carotene, vitamin B ₁ , B ₂ , and C, nicotinic acid, linoleic acid, betaine, pisaliene and β-cystosterol ( It contains a large amount of β-sistosterol) and various inorganic ingredients, and it has been recognized for its efficacy in tonic, adult disease prevention and treatment, eyesight protection, skin care, mental concentration improvement, and blue blood effect, and has been used as an essential medicine for many years. In addition, it is widely used as an additive of a drink material in modern medicine, and it has been found to prevent fatty liver formation, especially when drinkers take it.

Goji berries can be cultivated in various parts of Korea, but it is found to have a deep taste and aroma produced in Jindo, where the temperature is warm.

As such, goji berries known to have various effects have been produced mainly as a mixture of various herbal medicines such as schisandra chinensis, ganoderma lucidum and jujube, mainly as teas, beverages and liquor.

Patent publication related to the manufacturing method of tea or other beverages using conventional wolfberry relates to Patent Publication No. 91-6938, "Method of manufacturing a wolfberry drink," which contains raw materials such as wolfberry, schisandra chinensis, jujube and jujube in water After condensation by heating, the mixture of honey, sugar, fructose, citric acid, sodium citrate, sorbitol powder, vitamin C, etc. together with purified water is used. The manufacturing method of can be seen.

Such a conventional patent document can be seen that related to beverages and alcoholic beverages using goji, but all these are related to a complex drink containing gojija to produce a mixture of goji and other herbal ingredients, not just pure gojija have.

However, few attempts have been made to formulate the ingredients of wolfberry alone, rather than a method for producing a complex beverage including wolfberry.

The present inventors have conducted intensive studies on goji berries to find ingredients beneficial to health from natural products, and as described below, the extracts of goji berries and leaves of goji berries can effectively reduce blood lipid components of menopausal women. It was confirmed to complete the present invention.

Accordingly, it is an object of the present invention to provide a pharmaceutical and food composition for improving hyperlipidemia, hypercholesterolemia, including hot water extracts from the fruits and leaves of wolfberry.

Further objects and advantages of the invention will be apparent from the description in the following specification.

The present invention provides a medicament and food composition for improving hyperlipidemia, hypercholesterolemia, including hydrothermal extracts from the fruits and leaves of wolfberry.

The composition according to the invention can be prepared by methods conventional in the pharmaceutical art. Specifically, 200-250 g of dried wolfberry and dry wolfberry leaves were added with 3 liters of distilled water, and the mixture was concentrated under reduced pressure for 2 hours and 30 minutes at a temperature of about 100 ° C. with a water bath, and the extract was filtered and lyophilized to obtain powder. It can be diluted according to use.

The pharmaceutical and food compositions of the present invention may be best suited for the improvement of hyperlipidemia and hypercholesterolemia, especially in menopausal women, and those skilled in the art use standard diagnostic techniques for individuals suspected of suffering from such diseases, conditions and abnormalities. Can be easily grasped.

The pharmaceutical composition of the present invention can be formulated in combination with a known medical carrier. Generally, the active ingredient is combined with a pharmaceutically acceptable liquid or solid carrier, and a solvent, a dispersant, an emulsifier, a buffer, a stabilizer, an excipient, a binder, a disintegrant, a lubricant, and the like are added as needed, and the tablet is purified. And solid solutions such as granules, powders, powders, and capsules, liquids such as ordinary liquids, suspensions, and emulsions. Moreover, it can also be set as the dry product which can be made into a liquid state by addition of a suitable carrier before use.

The pharmaceutical composition of the present invention can be administered by any of parenteral agents such as oral preparations, injections, and drops.

A medical carrier can be selected according to the said dosage form and formulation, and, in the case of an oral preparation, starch, lactose, white sugar, mannitol, carboxymethylcellulose, corn starch, an inorganic salt, etc. are used, for example. Moreover, in preparation of an oral preparation, you may mix | blend a binder, a disintegrating agent, surfactant, a lubricating agent, a fluidity promoter, a copper, a coloring agent, a fragrance | flavor, etc. further.

On the other hand, in the case of parenterals, distilled water for injection as a diluent, saline solution, glucose aqueous solution, vegetable oil for injection, sesame oil, peanut oil, soybean oil, corn according to a conventional method It is melt | dissolved or suspended in oil, propylene glycol, polyethyleneglycol, etc., and it is prepared by adding a disinfectant, a stabilizer, an isotonicity agent, a non-fatting agent etc. as needed.

The pharmaceutical composition of the present invention is administered by a suitable route of administration according to the formulation form. The administration method need not be particularly limited and can be administered by internal content, external application, and injection. Injections can be administered, for example, intravenously, intramuscularly, subcutaneously, intradermally or the like.

The dosage of the pharmaceutical composition of the present invention is appropriately set in accordance with the form of the preparation, the method of administration, the purpose of use, and the age, weight, and symptoms of the patient to be applied thereto, but is not constant but generally used in the preparation of the active ingredient. The amount is, for example, 0.1-40 mg / kg per adult, and may be administered 1-6 times a day. However, those skilled in the art will appreciate the pharmacokinetic properties of certain reagents and their mode and route of administration; Age, health and weight of the recipient; It will be appreciated that the dosage will vary depending on known factors such as the nature and extent of the symptoms, the type of concurrent treatment, the frequency of treatment and the desired effect.

The composition of the present invention can also be used as a health functional food composition by the action of lowering blood lipid concentration.

The formulation of the functional food composition according to the present invention can be formulated in the form of a beverage, such as, for example, oral, pouch, or drink, according to conventional methods in the art.

The dosage of the food composition of the present invention is appropriately set according to the form of the preparation, the method of administration, the purpose of use, and the age, weight, and symptoms of the patient to be applied thereto, but the amount of the active ingredient contained in the preparation is generally not constant. Such as 0.1 to 40 mg / kg per adult, preferably 0.4 to 40 mg / kg. Of course, since the dose varies depending on various conditions, an amount smaller than the dose may be sufficient, or it may be necessary beyond the range.

The food composition according to the present invention may be prepared according to the form of the composition desired by conventional supplements or additives or sweeteners such as licorice, vitamin C, citric acid, nicotinic acid, sodium benzoate, aspartame, saccharin, pectin, malitol, sorbitol, xylitol, One or more ingredients selected from the group consisting of guar gum, skim milk powder, and oligosaccharides can be added to increase palatability or aesthetics.

They are suitably used at about 0.01 to 20% by weight based on the total weight of the composition of the present invention.

Drinking water, for example, put the wolfberry extract in 0.01 to 20% by weight, licorice 0.01-2% by weight, citric acid 0.01-2% by weight, malic acid 0.01-2% by weight, taurine 0.1-2% by weight, vitamin C 0.01-2% by weight, 0.01-2% by weight of vitamin B1, 0.01-2% by weight of biotin, 0.01-2% by weight of liquid fructose, or the like can be added alone or mixed to prepare a functional beverage.

<Example>

Hereinafter, the present invention will be described in more detail with reference to Examples. However, these are merely exemplary and are not intended to limit the present invention to them. In the data of Examples and Experimental Examples of the present invention, the experimental results for each group are expressed as the average standard deviation. Statistical analysis of each measurement was performed by using an unpaired t-test for each sample group compared to the normal control group, and it was considered that there was a significant difference when the P value was less than 0.05.

Example  1: wolfberry and Goji leaf  Powder and Extract Tablets

Goji berries and goji leaves used in this embodiment was used by Jindo-gun Jindogi Free Trade Farming Association Jeonnam produced by the environment-friendly organic farming method in 2005. 200 g of dried wolfberry and 250 g of dry wolfberry leaves were added with 3 L of distilled water, and then concentrated by distillation under reduced pressure for 2 hours and 30 minutes at a temperature of about 100 ° C with Daewoong tangtang (DWP-9900T, South Korea). After filtering with Whattman paper No. 1 and freeze drying using a freeze dryer (SFDSM06, Samwon, Korea) to obtain a dry extract 100g as a powder. This powder was diluted with distilled water and used in the subsequent examples and test examples unless otherwise noted. In subsequent test examples, the dry powder was diluted with distilled water to be administered as drinking water to each animal test group to verify the effect, and 100 mg / kg was administered daily.

Example 2: Preparation of Functional Wolfberry Pouch Products

1 g of licorice, 20 g of citric acid, 17 g of aspartame and 30 g of vitamin C were added to 100 g of Goji berry extract of Example 1, and the rest was added to purified water to prepare 2 l of drinking water and vacuum-packed in a conventional manner to prepare a pouch. . As a result, the beverage of the present invention obtained a favorable response in terms of mouth feel, taste, and comprehensive evaluation with conventional beverage products.

Example 3: Pharmaceutical Formulations

Form of Formulation (Tablet)

80 mg of wolfberry extract of the present invention

Lactose 50 mg

Starch 20 mg

5 mg magnesium stearate

15 mg of crystalline cellulose

One embodiment of the present invention is the use of said wolfberry extract as an active ingredient of the tablet shown above. Tablets may be prepared by conventional methods, and one preferred embodiment is in the form of tablets or soft capsules with conventional enteric coatings (eg hydroxypropylmethyl cellulose phthalate), sugar coatings or film coatings.

Test Example 1 Experimental Set Up and Derivation of Test Model

The experimental group on the osteoporosis prevention effect of goji and goji leaves was normal group. LCF), Goji berry leaves (LCL), and estrogen-treated group (E ₂ ), an osteoporosis prevention and treatment, were divided into five groups.

Bilateral ovarian extraction was performed under aseptic manipulation from 9 week-old Sprague-Dawley rats. Sterilize the surgical site and the surrounding area with 10% povidone iodine according to the usual preoperative procedures, and excision of both ovaries by excision of the skin, muscle, and peritoneum of the lower abdomen under aseptic manipulation, exposing both ovaries and excision Ligation and sutures. To observe the prevention of osteoporosis, goji and goji leaf were administered daily as drinking water for 8 weeks after ovarian extraction. In the most surgical group, peritoneal incision was performed in the same way, and the suture was resealed without extraction of the ovaries and water was administered to the normal group as drinking water.

Test Example 2: Estrogen Hormone Injection and Weight Change Test

The uterus is all estrogen dependent and secreted only from the ovary, so when the ovary is removed, uterine atrophy occurs and bone loss is significantly increased. One cause of osteoporosis is a lack of estrogen. In this experimental example, 0.001 mg of estrogen per 100 g of body weight was injected once a day for 8 weeks from the day after ovarian extraction to the estrogen-administered group as a hormonal therapy.

Nine-week-old rats weighing 220 ± 5 g were purchased from Damul Science Co., Ltd., Daejeon Metropolitan City, and adapted to normal breeding environment for one week at the College of Oriental Medicine, Dongshin University. The body weight was measured at 8 weeks old and the change was observed. All rats used in the experiment were observed after fasting for 12 hours before sacrifice. The normal group and osteoporosis group provided general feed and water, and 8 hours of goji and goji leaves were administered to the ovarian extraction group and the results are shown in Table 1 and FIG. 1. 1 is a graph showing weight change in rats. Sham: The most surgical group, OVX: Ovarian osteoporosis group, LCF, LCL and E ₂ : After each ovarian extraction, wolfberry, wolfberry leaf and estradiol group were administered. Each point is represented by mean ± SD (n = 7).

Test group Initial weight (g) Final weight (g) Sham 229 ± 1.7 279 ± 1.7 OVX 225 ± 3.2 330 ± 5.4 OVX + LCF 225 ± 2.5 328 ± 3.0 OVX + LCL 229 ± 2.2 322 ± 2.5 OVX + E ₂ 231 ± 3.0 240 ± 3.3

As can be seen from the results of Table 1 and FIG. 1, the body weight of the osteoporosis group was significantly increased to 330 ± 5.4 g after 8 weeks, and decreased slightly by 328 ± 3 g and 322 ± 2.5 g, respectively. There was no difference. In the present experiment, the removal of the ovaries of rats increased the growth rate and resulted in weight gain, and the weight gain rate was lower in the group treated with goji berry and goji leaf compared to the ovarian-only group.

Test Example 3: Changes in the Uterus and Histological Observation

To determine whether the ovarian removal was successful in the rat, the uterine weight and histological changes of the uterine tube were examined. The result is shown in FIG. 2 is a graph showing the effect of LCF and LCL on uterine body weight in ovariectomized rats. Each point is represented by the mean value SD (n = 7). From the results of FIG. 2, the uterine weight was significantly decreased in the osteoporosis group, but there was a slight increase in the group treated with Goji berry leaves and the estrogen-administered group was significantly increased. Uterine weight loss and uterine atrophy revealed a successful ovarian resection. 3 is a cross-sectional picture of the uterus of the test model. A: the most surgical group, OVX: ovarian isolated osteoporosis control rats, C, D and E: after each ovarian extraction, wolfberry, wolfberry leaves and estradiol group. Hematoxylin and eosin stained sections. The photo is shown at the original magnification x 20. Figure 3 is extracted from the uterine tissue of the rat and fixed with 4% paraformaldehyde for 24 hours, and then embedded in paraffin and the tissue was sliced to a thickness of 5 ㎛ with a microtome. After attaching the sliced tissue on the slide glass, remove the paraffin from xylene and soak it for 5 minutes in order of decreasing concentration such as 100%, 90%, and 80% ethanol, and wash it in running water for 10 minutes. It was. After the slides were dried, HE stained, mounted with Canadian balsam, observed with an optical microscope, and photographed. Results The diameter of the uterine canal was significantly decreased in the osteoporosis and goji berry group compared to the normal group. The diameter of the uterine tube was slightly increased compared to the osteoporosis group, and the estrogen diameter was similar to that of the normal group.

Test Example 4 Change in Serum Osteocalcin Content

After serum separation, osteocalcin levels were measured using a rat Osteocalcin EIA kit (Biomedical Technologies Inc., USA). After incubating the isolated serum in 96-well plates, the washed plates were reacted with a secondary antibody (second Ab, goat polyclonal) with high specificity for the C-terminal region of the rat osteocalcin peptide. Conjugation with Donkey anti-goat IgG peroxidase. TMB (3,3,5.5-tetramethyl benzidine) -substrate was aliquoted and reacted, and then absorbance was measured using an EIA reader (TECAN, Austria) by adding a coloring agent. Osteocalcin is tightly bound to calcium in the structure of the bone. Figure 4 shows the effect of LCF and LCL on serum osteocalcin in uterine isolated mice. Bars are represented as mean ± SD (n = 10). P <0.05: Significance difference compared to the most surgical group rats. The osteocalcin content in the serum of FIG. 4 was 444.6 ± 26.9 ng / ml of goji berry and 407 ± 18.9 ng / ml of goji berry, which was significantly increased compared to 107 ± 3.52 ng / ml of osteoporosis group and 63.8 ± 5.7 ng / ml of normal group. Estrogen-administered groups also increased. These results are thought to be able to detect osteoclast activity according to the decrease in osteoblasts during osteoporosis. The osteoporosis group showed decreased results in this experiment, which is consistent with the reports of several researchers. Significantly high significance was seen in the administration group.

Test Example  5: alkaline phosphatase ( ALP Activity

The activity of alkaline phosphatase was measured by using the test equipment Hirachi 7170A (Cheil Chem) using Daiizhi reagent (International Corporation, Japan) according to the UV method. Alkaline posopotase is a glycoprotein secreted by osteoblasts and is a bone marker commonly used in the clinic. ALP has been reported to increase activity after ovarian extraction. 5 is a graph showing the effect of LCF and LCL on alkaline phosphatase activity in uterine isolated mice. Bars are represented as mean ± SD (n = 7). * P <0.05: Significance difference compared to the most surgical group rats. Referring to the results of FIG. 5 according to this test example, there was a decrease in activity in Goji 158 ± 2.2 U / L and Goji leaf group 161 ± 2 U / L compared to osteoporosis group 182 ± 8.1 U / L. Among them, the Goji Wolf administration group showed close to the estrogen group.

Test Example 6: Total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride content

Total cholesterol and triglycerides were measured at 546 nm and 505 nm wavelengths using Cholesterol-SL Kit and Triglyceride-SL Kit (ELITECH, France), respectively. The effect on blood lipid pattern is shown in Table 2. Table 2 shows total cholesterol, high density lipoprotein cholesterol, and triglyceride content in the experimental model.

Total Cholesterol, High Density Lipoprotein (HDL) Cholesterol, and Triglyceride Content in the Serum of Most Syndrome Rats and Treated and Untreated Ovarian Rats Treated with LCF, LCL and E ₂ Test group Cholesterol content (mg / dL) HDL cholesterol content (mg / dL) LDL cholesterol content (mg / dL) Triglyceride Content (mg / dL) Sham 91 ± 4.5 8.2 ± 0.65 8.2 ± 0.65 40 ± 2.1 OVX  105 ± 4.2 *  12.6 ± 0.89  12.6 ± 0.89 38 ± 6.4 OVX + LCF 86 ± 3.9  8.8 ± 0.45 *  8.8 ± 0.45 * 36 ± 4.1 OVX + LCL 94 ± 4.3  9.7 ± 0.52 *  9.7 ± 0.52 * 38 ± 0.9 OVX + E ₂  77 ± 1.3 *  3.3 ± 0.23 *  3.3 ± 0.23 *  52 ± 7.2 *

As can be seen from the above results, goji and goji leaf administration group lowered total cholesterol and triglyceride levels in blood, high HDL cholesterol and low LDL cholesterol compared to osteoporosis group. Therefore, goji berry extract according to the present invention is believed to lower the accumulation of triglycerides in the blood and have an anti-arteriosclerosis effect.

Test Example 7: Morphological Changes of the Femur

The femur was separated and prefixed with prefixed 2.5% glutaraldehyde (phosphate buffer, pH 7.4) for 2 hours. After pretreatment, the tissues were demineralized for at least two weeks, cut vertically, washed three times with the same buffer every 10 minutes, and then fixed with 2% 1% osmium tetroxide, followed by 3 Washed twice. After washing, the samples were dehydrated with ethanol in increasing order and completely dried at room temperature. Observation and photographing were performed with an optical microscope. Fig. 6 is a longitudinal scanning electron micrograph of the right thigh of each experimental model 8 weeks after ovarian extraction. A: the most surgical group, OVX: ovarian osteoporosis control rats, C, D and E: after each ovarian extraction, wolfberry, wolfberry leaves and estradiol group. According to the results of FIG. 6, the loss of spongy bone residues was most remarkable in the osteoporosis group compared to the normal group, and the estrogen-administered group was the most insignificant. Goji berries and goji leaf influenced the decrease in bone loss progress.

Test Example 8: Histological observation for comparison of osteoclasts and osteoblasts in each group in demineralized samples of femur

At 8 weeks after surgery, the femoral bones of the rats were measured and their weights were measured after periosteal separation. The osteoporosis group was slightly lower in the weight of the femur per body weight than the normal group, and there were no significant differences in the weight change in the group treated with goji, goji leaf and estrogen. 7 is a photograph showing the histological change of the right femur cross section of each experimental model. A: the most surgical group, B, b: OVX, ovarian osteoporosis control rats, C, c, D, d and E, e: after each ovarian extraction, wolfberry, wolfberry leaves and estradiol groups are shown. Hematoxylin and eosin stained sections, original magnification x40, x200. Figure 7 after the separation of the femur was fixed for 24 hours using 4% paraformaldehyde for 24 hours or more and then the femur was transversely cut. After embedding with paraffin, which is a conventional tissue fabrication process, the tissue was sectioned to a thickness of 6 μm with a microtome. After attaching the sliced tissue on the slide glass, remove the paraffin from xylene and soak it for 5 minutes in order of decreasing concentration such as 100%, 90%, and 80% ethanol, and wash it in running water for 10 minutes. It was. After the slides were dried, HE stained, mounted with Canadian balsam, observed with an optical microscope, and photographed. As shown in FIG. 7, the bone tissues of the mice that caused osteoporosis by ovarian extraction compared to the normal bone tissues showed significantly more bone loss. Goji berry, Goji berry leaves and estrogen-treated groups showed increased osteoblasts and decreased osteoclasts, indicating that bone loss was affected. This was confirmed histologically in this study in relation to the report that estrogen deficiency is related to osteoblast function deficiency in postmenopausal osteoporosis among several types of osteoporosis.

As described above, as described above, the functional food for improving hyperlipidemia and hypercholesterol containing the goji berry extract according to the present invention is derived from natural products and has no side effects, especially in menopausal women. Since suppression can be used in various ways, such as food ingredients for the improvement of related diseases.

Claims (2)

A food composition for improving hyperlipidemia and hypercholesterolosis, comprising hot water extract from fruit and leaves of Goji berries as a main component. The composition of claim 1, wherein said composition is provided in the form of an oral preparation, a pouch preparation, a beverage preparation, a beverage.

Images